<DOC>
	<DOCNO>NCT00621894</DOCNO>
	<brief_summary>The purpose study assess ability LGD-4665 give daily mouth increase platelet count treatment patient ITP ( immune thrombocytopenic purpura ) . LGD-4665 increased platelet count safely tolerably compare placebo healthy volunteer . This study examine safety , tolerability efficacy 7.5 mg capsule LGD-4665 increase platelet compare placebo , randomize 2:1 , blind treatment 6 week . Evaluation platelet count , bleed score safety parameter do weekly . All patient eligible continue active , open LGD-4665 treatment additional 12 week optimal adjustment dose patient .</brief_summary>
	<brief_title>Oral LGD-4665 Versus Placebo Adults With Immune Thrombocytopenic Purpura ( ITP ) 6 Weeks Plus Open Treatment Continuation</brief_title>
	<detailed_description>This Phase IIA study two part design . - Part 1 randomize , double-blinded , placebo-controlled treatment 7.5 mg/day LGD-4665 versus placebo approximately 24 patient ITP treat least one prior therapy ITP . Patients randomize ratio 1:2 ( placebo : 7.5 mg/day LGD-4665 ) 6 week treatment . Platelet count , bleed score , vital sign , physical exam laboratory test assess weekly . Treatment group analyze efficacy percentage patient platelet count two time baseline ≥ 50,000/uL 6 week treatment , safety adverse event , vital sign , physical exam , laboratory test use ITP rescue medication transfusion . - Part 2 extension study treatment open label LGD-4665 . All patient participate Part 1 randomize double-blind treatment Ph IIA trial eligible continue open label treatment LGD-4665 3 month appropriate dose safe maintenance platelet count ( ≥ 50,000/uL ≤ 200,000/uL ) . Assessments effectiveness safety make 2 4 week interval .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Adults 18 year old Diagnosis ITP least 3 month consistent ASH guideline Treated one prior therapy ITP platelet count &lt; 30,000/µL &lt; 50,000/µL stable oral corticosteroid ≥ 4 week , support 2 platelet count prior 30 day Laboratory result within normal range except follow analytes Hemoglobin ≥ 10 g/dL Absolute neutrophil count &gt; 1000/mL ALT ≤ 1.5X ULN AST ≤ 1.5X ULN Creatinine &lt; 1.5X ULN Bilirubin &lt; 1.5X ULN BUN &lt; 1.5X ULN PT &lt; 1.5X ULN aPTT &lt; 1.5X ULN Women childbearing potential must negative serum pregnancy test within 4 day prior first dose study treatment agree practice approve method contraception abstinence sexual intercourse . Willing sign write informed consent Exclusion criterion : History heart attack cardiovascular disease Known history arterial venous thrombosis More 3 risk factor thromboembolic event ( diabetes , smoker , use oral contraception , use estrogen therapy , hypertriglyceridemia , average cholesterol &gt; 240 mg/dL , treatment hypertension ) Active cancer history bone marrow disorder Women pregnant nursing History alcohol/drug abuse dependence within one year Listed medication dose within : 4 week first dose study treatment : Use Rituximab Use cytotoxic agent Use Cyclosporine immunomodulators Use investigational drug 2 week first dose study treatment : Use Danazol Use Azathioprine Use Mycophenolate mofetil pulseddose steroid 1 week first dose study treatment : Use AntiD ( WinRho® ) Use IVIG Had platelet transfusion Use herbal/dietary supplement ( exclude vitamin mineral supplement ) 3 day first dose study treatment Use aspirin , aspirin contain compound salicylates milk magnesia nonsteroidal antiinflammatory drug ( unless prescribe heart disease ) History platelet aggregation would prevent measurement platelet count Known active infection HIV , hepatitis B , hepatitis C In Investigator 's opinion , patient able comply requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Immune thrombocytopenic purpura</keyword>
	<keyword>thrombopoietin mimetic</keyword>
	<keyword>ITP</keyword>
</DOC>